This is Dimension 7 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
Part 7 of 7 — The Patient Marketing Diligence (PMD) Framework
Six dimensions in, you have a detailed operating picture. Dimension 7 turns it into the single question an investment committee actually needs answered: is this growth bought, or built?
Bought growth is rented. It depends on spend that has to continue, on demand that was already there, or on numbers nobody verified, and it may not survive a change of ownership. Built growth is structural. It’s verified, diversified, driven by demand the target created, and able to scale. The Patient Marketing Diligence framework exists to tell the two apart, and this last dimension, Growth Quality Synthesis, is where it commits to an answer.
How the First Four Dimensions Roll Up
Dimension 7 isn’t scored on its own. It’s a derived read of the first four dimensions, each of which tests one reason growth might be rented:
- Acquisition Economics asks whether cost per patient is holding up over time, or being propped up by spend cuts. Part 1
- Demand Composition asks how much of paid performance is brand capture instead of new demand. Part 2
- Measurement Integrity asks whether the reported numbers can be verified against real patient records. Part 3
- Concentration & Exposure asks how much depends on a single platform or market. Part 4
Scalability and Operating Resilience (Part 5 and Part 6) then qualify how far the answer can be trusted forward: whether the engine can grow, and whether it survives a handoff.
Why This Can’t Be Graded Independently
It’s tempting to score growth quality as its own category, but doing so would double-count the same evidence or invent a new opinion. The point of this dimension is synthesis. A target with verified attribution, a majority of non-brand conversions, diversified channels, and a stable cost trend has built growth, and no separate test is needed to say so. A target with unverified numbers and heavy brand capture has bought growth, even if every headline metric looks excellent.
The composite is scored on a five-point scale, from Built at the top, where growth is demonstrably structural, down to Bought at the bottom, where results are materially a function of brand-term harvesting or unverifiable attribution. The middle, Mixed, is an honest answer for many targets: some demand is real and some is rented, and the work is separating the two.
The Hard Flag Rule
One rule keeps the composite honest. If any of Dimensions 1 through 4 carries a Hard Flag, Growth Quality is capped at a 2, regardless of the weighted math.
The reasoning is simple. A Hard Flag in a foundational dimension, such as numbers that can’t be reconciled with real patient records, or a brand and non-brand split management won’t produce, invalidates confidence in the growth story itself. A strong score elsewhere can’t average that away. Capping the composite stops a good average from hiding a disqualifying finding.
The Number That Belongs in the IC Memo
The reason this matters is the investment memo. Committees read a narrative about growth: how fast it’s happening, what drives it, what the plan assumes. This dimension turns that narrative into a defensible grade with evidence behind it. Instead of “marketing is performing well,” the memo can say that growth is mostly built, with specific pockets of dependency on one platform and one market, and these are the conditions that would change the view.
That’s also what turns diligence into valuation. Built growth supports a growth multiple because it transfers. Bought growth supports a discount, a structure tied to performance, or a closer look at what the target is really selling. Either is a better position than finding out after close.
Scoring the Whole Framework
Each dimension is scored from 1 to 5, with Growth Quality derived from the first four, and the scores are weighted into a composite and read alongside the Soft and Hard Flags. The full document walks through the criteria, the evidence to request, and how to run the scorecard. It’s designed for a deal team, or for a specialist brought in to run it, because pulling the evidence takes access and judgment that a questionnaire can’t replace.
Why It Matters for the Deal
Patient acquisition drives much of the growth story in healthcare platforms, yet it’s still diligenced less formally than finance, commercial, or technology. Treating it as its own category gives a deal team a common language and a repeatable standard. The question is simple, and answering it takes work: is this growth bought, or built?
This is Dimension 6 of 7 in the Patient Marketing Diligence Framework, a standard for evaluating whether a healthcare target’s patient acquisition is built to last or bought to look good for a sale.
You’ve now seen the whole framework in pieces. Get it in one document: all 7 dimensions, complete scoring criteria, evidence sourcing, red flag triggers, and the one-page scorecard, delivered free.
